drugset / Trial / NCT04371926

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

NCT04371926

RandomizedParallel-groupSingle-blindPrevention

Summary

Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.

Timeline

Start
2020-06
Primary completion
2021-06
Completion
2021-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroxychloroquine Small molecule 200 mg
Comparator Hydroxychloroquine Small molecule 400 mg

Indications